Spots Global Cancer Trial Database for low risk
Every month we try and update this database with for low risk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer | NCT03159676 | Prostate Cancer | Proton beam | 18 Years - | Mayo Clinic | |
| Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | NCT01898104 | Colorectal Canc... | preoperative ra... Valproic Acid Capecitabine | 18 Years - 70 Years | National Cancer Institute, Naples | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Study of Stereotactic Radiotherapy for Breast Cancer | NCT03043794 | Breast Cancer | Stereotactic Bo... | 50 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Optimum Induction Therapy of Low-risk APL | NCT05832320 | Acute Promyeloc... Induction Thera... Oral | Etoposide Daunorubicin | 18 Years - 75 Years | Peking University People's Hospital | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| Three Dosing Schedules of Oral Rigosertib in MDS Patients | NCT02075034 | Myelodysplastic... | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer | NCT03531099 | Prostate Cancer | treatment with ... PSA dosage MRI Questionnaires Prostatic biops... | 50 Years - 80 Years | Hospices Civils de Lyon | |
| Shared Decision Making in Low Risk Prostate Cancer | NCT01673581 | Prostate Cancer | Survey | 18 Years - | Massachusetts General Hospital | |
| Improve Colorectal Cancer Prevention by Motivational and Community-based Approaches | NCT05568667 | Colorectal Canc... | Low risk Moderate risk High risk | 18 Years - 80 Years | Centre Leon Berard | |
| Shared Decision Making in Low Risk Prostate Cancer | NCT01673581 | Prostate Cancer | Survey | 18 Years - | Massachusetts General Hospital | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| Pilot Study on Focal Prostate Radio-Frequency Ablation | NCT01423006 | Prostate Cancer | Radio-Frequency... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer | NCT01617161 | Prostate Cancer | Proton Beam The... Intensity Modul... | 18 Years - | Massachusetts General Hospital | |
| Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer | NCT01617161 | Prostate Cancer | Proton Beam The... Intensity Modul... | 18 Years - | Massachusetts General Hospital | |
| Improve Colorectal Cancer Prevention by Motivational and Community-based Approaches | NCT05568667 | Colorectal Canc... | Low risk Moderate risk High risk | 18 Years - 80 Years | Centre Leon Berard | |
| Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer | NCT05609435 | Breast Cancer | REASSURE | 18 Years - 95 Years | University of Wisconsin, Madison | |
| Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer | NCT05609435 | Breast Cancer | REASSURE | 18 Years - 95 Years | University of Wisconsin, Madison | |
| Shared Decision Making in Low Risk Prostate Cancer | NCT01673581 | Prostate Cancer | Survey | 18 Years - | Massachusetts General Hospital | |
| Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | NCT01898104 | Colorectal Canc... | preoperative ra... Valproic Acid Capecitabine | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Study of Stereotactic Radiotherapy for Breast Cancer | NCT03043794 | Breast Cancer | Stereotactic Bo... | 50 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pilot Study on Focal Prostate Radio-Frequency Ablation | NCT01423006 | Prostate Cancer | Radio-Frequency... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q | NCT01081431 | Myelodysplastic... | Lenalidomide | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
